Fosfluconazole
Structural formula | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
![]() |
||||||||||
General | ||||||||||
Non-proprietary name | Fosfluconazole | |||||||||
other names | ||||||||||
Molecular formula | C 13 H 13 F 2 N 6 O 4 P | |||||||||
External identifiers / databases | ||||||||||
|
||||||||||
Drug information | ||||||||||
ATC code | ||||||||||
Drug class | ||||||||||
properties | ||||||||||
Molar mass | 386.25 g · mol -1 | |||||||||
safety instructions | ||||||||||
|
||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Fosfluconazole is an antifungal from the triazole group and an ester of the also antifungal active fluconazole with phosphoric acid . It inhibits the ergosterol biosynthesis.
pharmacology
Fosfluconazole inhibits 14 α- demethylase, a fungus-specific cytochrome P450 isoenzyme ( CYP51A1 ), which is responsible for the conversion of lanosterol into ergosterol . Ergosterol precursors are built into the membrane and the permeability for cell components increases.
Finished medicinal products
Prodif ( J )
There are no approvals in Germany, Austria and Switzerland.
literature
- Synthesis: Bentley A et al. The Discovery and Process Development of a Commercial Route to the Water Soluble Prodrug, Fosfluconazole. Organic process, research and development (2002); 6 (2): 105-112; doi : 10.1021 / op010064 .
- Pharmacology: Sobue S et al. Pharmacokinetics and safety of Fosfluconazole after single intravenous bolus injection in healthy male Japanese volunteers . In: J Clin Pharmacol 2002; 44 (3): 284-292; PMID 14973307 .
- Studies: Kawakami Y et al. Nonclinical studies and clinical studies on fosfluconazole, a triazole antifungal agent (Prodif). Nippon Yakurigaku Zasshi 2004; 124 (1): 41-51; PMID 15226621 .
Individual evidence
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.